SavedAdd your journal

Journals / Acta Oncologica Turcica / 2014 / Cilt: 47 Sayı: 3

Potential Curative Role of Chemotherapy in Patients with Metastatic Colorectal Cancer Who Had Complete Response to First-line Treatment

Birinci Hat Kemoterapi ile Tam Yanıt Alınan Metastatik Kolorektal Kanserli Hastalarda Kemoterapinin Potansiyel Küratif Rolü

Umut Varol
Ahmet Alacacıoğlu
İbrahim Yıldız
Mustafa Oktay Tarhan
Pages
62–63
Publication Date
2014-12-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

Varol, U., Alacacıoğlu, A., Yıldız, İ., Tarhan, M. O. (2014). Potential Curative Role of Chemotherapy in Patients with Metastatic Colorectal Cancer Who Had Complete Response to First-line Treatment. Acta Oncologica Turcica, Cilt: 47 Sayı: 3, 62–63. https://doi.org/10.5505/aot.2014.08370

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Tanida T, Ohue M, Noura S, et al. Long-term complete response of unresectable liver metastases from colorectal cancer. Hepatogastroenterology 2010; 57:764-7
  2. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases chemotherapy. Cancer 2010;116:1502-9 cancer after
  3. Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 2007;25:3469-74
  4. Ferrarotto R, Pathak P, Maru D, et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011;10:178-82
  5. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45
  6. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. The Lancet Oncology 2014;105:1065-75